

**Review Article**

Enhancement of sAPP α as a Therapeutic Strategy for Alzheimer's and Other Neurodegenerative Diseases

Patricia Spilman¹, Barbara Jagodzinska¹, Dale E Bredesen^{1,2} and Varghese John^{1*}

¹Department of Neurology, Drug Discovery Laboratory, Easton Center for Alzheimer's Disease Research, Geffen School of Medicine, University of California, Los Angeles, CA, USA

²Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, USA

Abstract

Soluble, secreted Amyloid Precursor Protein- α (sAPP α), a product of α -secretase (ADAM10) cleavage of Full Length-APP (FL-APP), is a trophic factor critical for synaptic complexity and maintenance. As cleavage at the α -site of APP precludes the β -site cleavage that is the first step in Amyloid β (A β) production, enhancing sAPP α production may not only support and restore neuronal health, but may also decrease the generation of anti-trophic A β . Over-production or reduced clearance of A β is a hallmark of Alzheimer's Disease (AD), and recent findings suggest it also plays a role in other neurodegenerative diseases and neurological conditions, such as Amyotrophic Lateral Sclerosis (ALS), Cerebral Amyloid Angiopathy (CAA), and Traumatic Brain Injury (TBI). Yet decades of focus on A β -lowering strategies alone including passive and active immunotherapy and γ -secretase and BACE1 (BACE) inhibition have yet to yield positive clinical results. Clinical trials of several BACE inhibitors are underway in AD patients, and although there is optimism about this strategy, there are also concerns about mechanism-based side-effects of these drugs. A truly effective therapy would not only slow the degenerative process underlying onset and progression of the disease, it should also restore healthy neuronal function. It is very likely this will comprise combination therapy utilizing more than one drug or intervention. Molecules that enhance sAPP α may be a safe, effective component of a multi-modal therapeutic approach to AD and other neurodegenerative diseases, and have the potential to increase neuronal health by providing trophic support and disrupting neurodegenerative mechanisms.

***Corresponding author:** Varghese John, Department of Neurology, Drug Discovery Laboratory, Easton Center for Alzheimer's Disease Research, Geffen School of Medicine, 3131 Reed, 710 Westwood Plaza, UCLA, Los Angeles, CA 90025, USA, Tel: +1 3102064345; E-mail: vjohn@mednet.ucla.edu

Citation: Spilman P, Jagodzinska B, Bredesen DE, John V (2015) Enhancement of sAPP α as a Therapeutic Strategy for Alzheimer's and Other Neurodegenerative Diseases. J Alzheimers Neurodegener Dis 1: 001.

Received: June 16, 2015; **Accepted:** July 13, 2015; **Published:** August 03, 2015

Keywords: ADAM10; AD; ALS; BACE1; CAA; sAPP α ; Stroke; TBI; γ -secretase

Introduction

Therapeutics for Alzheimer's Disease (AD)

The number of cases of Alzheimer's Disease (AD) - the most prevalent age-associated dementia - is expected to increase rapidly as society ages, rising from approximately 5 million at present to 15 million cases by 2050 in the US [1], and currently there are no treatments that prevent onset or alter the course of the disease. AD is a progressive neurodegenerative disorder characterized by the presence of senile plaques, composed mainly of Amyloid β peptide (A β) [2,3], and the development of neurofibrillary tangles of hyper-phosphorylated tau (ptau) in brain tissue [4,5]. AD patients suffer from deficits in cognition, learning and memory, and exhibit impaired Long-Term Potentiation (LTP) [6] and a consistent deficit in cholinergic neurotransmission. The currently approved therapeutics include the acetylcholinesterase inhibitors donepezil, galantamine, rivastigmine, and tacrine which inhibit the breakdown of acetylcholine at the neuronal junction, and the N-Methyl-D-Aspartate (NMDA) receptor antagonist memantine, which reduces the excitotoxicity that results from NMDA receptor overstimulation in AD. Recently, the FDA has approved a fixed-dose combination of memantine hydrochloride extended release (Namenda XR) and donepezil hydrochloride (Namzaric) for moderate to severe AD-related dementia. These current therapeutics offer only temporary improvement in cognition and/or delay in progress of the disease, thus there is clearly a need for new approaches to and discovery of new targets for AD therapeutic development.

More recent approaches to AD therapeutic development include re-purposing the anti-epileptic drug levetiracetam to address the seizure-like activity manifest in many AD patients [7,8], use of anti-diabetic drugs including intranasal insulin [9,10], and development of BACE inhibitors [11-13], including our own APP-selective BACE inhibitors [14], to name a few. It is hoped that some of these new approaches will provide benefit in AD, but it is very likely that truly effective treatment for AD will require multiple therapeutics working in concert - similar to the approach used for AIDS therapy - to address the many deficits in the disease. One component of this multi-modal therapy should restore and promote normal neuronal function, rather than just arrest a single deleterious process underlying the disease. It is our hypothesis and that of others that enhancement of trophic peptide sAPP α , or the activity of the enzyme ADAM10, could play this key role in therapy.

A β plaques and the amyloid hypothesis in AD

The original evidence pointing to amyloid as causative in AD came from the finding of amyloid plaques in the brains of AD patients. It was ultimately determined that these plaques were comprised of Amyloid- β (A β) peptides [15,16] and based on the presence of these plaques in brain tissue and vessels in AD patients, Hardy and Allsop proposed the amyloid hypothesis of AD [3]. In this hypothesis, the overproduction and/or lack of clearance of A β , and particularly

A β 1-42, is the underlying pathological mechanism leading to manifestation of AD signs and symptoms. Much study has been directed to understanding the processes by which A β accumulation leads to neuronal damage. The identified effects include oxidative damage [17], synaptic dysfunction and excitotoxicity [18], inflammation [19], mitochondrial dysfunction [20], increased membrane permeability [21] and alteration of Wnt [22] and other cell signaling pathways.

Some of the strongest support for the amyloid hypothesis of AD comes from identification of mutations that lead to familial forms of Alzheimer's Disease (FAD). These mutations are found in APP, presenilin (executor of γ cleavage) 1 or 2 genes, and the ADAM10 gene [23]. All of these mutations result either in increased A β production or increased A β 1-42 production relative to other A β species, which in turn leads to Early Onset Alzheimer's Disease (EOAD). Furthermore, an A673T mutation in APP at the β -cleavage site has recently been described that protects against AD and cognitive decline in elderly persons in the absence of AD [24]. Subsequent studies showed this mutation decreased β cleavage of APP, and was associated with a slight reduction in aggregation of A β 1-42 peptides [25].

The great majority of AD cases, however, are sporadic and do not result from inherited mutations. These are classified as Late Onset Alzheimer's Disease (LOAD). Genetics can play a role in LOAD, as possession of either one or two Apolipoprotein E ϵ 4 alleles (ApoE ϵ 4) confers an increased risk for the development of AD [26]. Apolipoproteins bind A β and affect transport, aggregation and clearance as well as influence synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation [27]. Because there is close association with A β accumulation in ApoE ϵ 4 individuals and cognitive decline frequently leading to development of AD, this is further support for the amyloid hypothesis.

The manifestation of AD-like cognitive changes in the absence of amyloid plaques - if neurofibrillary tangles are present - is considered to be a tauopathy rather than AD. Some subjects with cognitive changes in the absence of AD-like pathology, as determined by amyloid PET imaging but with degenerative changes in 18 fluorodeoxyglucose PET scans and hippocampal volume, have also been identified. In one study, these Suspected Non-Alzheimer Pathology (SNAP) individuals comprised approximately one third of patients diagnosed with cognitive decline with age and most were found to have cerebrovascular disease or synucleinopathy [28]. Other conditions such as Lewy body dementia, depression, or multiple sclerosis may lead to manifestation of AD-like cognitive changes, but in the absence of amyloid pathology, are not defined as AD.

APP processing

A β originates from Full Length-Amyloid Precursor Protein (FL-APP) which may be cleaved via alternate pathways (Figure 1). In the anti-trophic pro-AD pathway, β -secretase (BACE1, BACE) interacts with FL-APP on the cell surface, leading to dimerization and endocytosis to an acidic compartment wherein it is cleaved to produce sAPP β and β CTF [29]. The β CTF fragment can then undergo γ -secretase cleavage, generating A β of a variety of species (lengths). Alternatively, in the trophic, anti-amyloidogenic anti-AD pathway, APP is cleaved by an α -secretase (putatively ADAM10) to generate the two fragments sAPP α and α CTF. These latter fragments [30] support synaptic maintenance and can inhibit the β pathway as

cleavage at the α site precludes β cleavage and because sAPP α itself is a BACE inhibitor [31,32].




Figure 1: APP acts as a "molecular switch".

Under trophic, anti-AD conditions wherein synapses are maintained, Full Length-APP (FL-APP) in the plasma membrane interacts with the α -secretase ADAM10 to generate sAPP α and α CTF (shown at left). As the α -site is within the A β cognate region, α -cleavage precludes A β formation. In addition, sAPP α itself can act as a BACE inhibitor [31,32] while α CTF is an inhibitor of γ -secretase [33]. Alternatively, in the anti-trophic pro-AD pathway, FL-APP can interact with BACE resulting in dimerization, endocytosis, and cleavage in the acidic endosomal compartment, generating sAPP β and β CTF. β CTF is then cleaved by γ -secretase in the plasma membrane, generating A β and the APP Intracellular Domain (AICD). The species (or length) of A β resulting from the γ -cleavage may vary depending upon the exact site of cleavage. A β may oligomerize, particularly in circumstances of high A β production. The oligomers may remain in the plasma membrane or be found in the cytoplasm or extracellular space, where ultimately they can aggregate and form plaques. A β oligomers may also interact with FL-APP (far right) initiating the formation of a dimer and cleavage by a caspase (putatively caspase 6) resulting in production of the anti-trophic C31 and APPneo fragments.

The interaction of APP cleavage products with each other and non-APP-derived proteins is complex and the mechanisms by which these APP fragments exert their many effects is not fully elucidated [34]. It is known, however, that α CTF can inhibit γ -secretase activity [33] as it contains an intact γ -cleavage site. β CTF, in similar fashion, inhibits a cleavage [35] which may explain, in part, the paradoxical increase in A β in the presence of low to moderate concentrations of γ -secretase inhibitors. In addition to BACE, FL APP can interact with A β oligomers or heparin [36] forming dimers that then can undergo C-terminal caspase cleavage resulting in the generation of APPneo and the toxic fragment C31, inducing cell death.

The pro-cognitive role of sAPP α is clear. In primary neuronal culture, sAPP α decreases excitability [37] and in synaptosomes, it increases synaptic elements [38]. The correlation of sAPP α to synaptic plasticity and maintenance is well-established *in vivo*. In Anderson et al., [39] a positive correlation was shown between performance in spatial memory tasks and CSF sAPP α in young and aged rats. Intracerebroventricular (ICV) treatment with sAPP α improved both motor and cognitive function in mice subjected to Traumatic Brain Injury (TBI), another pathological condition resulting in increased β -pathway processing of APP [40]. Recently, it was shown that acute sAPP α administration can rescue LTP in conditional APP/APLP knockout mice [41]. In humans, CSF sAPP α levels were seen to correlate positively with better cognitive performance [42] as determined by IQ, verbal ability, visuospatial function, immediate memory, episodic memory and various aspects of attention.

Mutations in ADAM10 and at APP α - and β -cleavage sites alter AD risk

Support for ADAM10 (a disintegrin and metalloprotease) as the α -secretase responsible for most sAPP α generation is based on the

finding of a missense mutation in ADAM10 that increases A β accumulation [43] while decreasing the sAPP α /sAPP β ratio. Suh identified two rare mutations (Q170H and R181G) in the prodomain ADAM10 that co-segregate with Late-Onset AD (LOAD). Both mutations attenuated the α -secretase activity of ADAM10 and increased BACE cleavage of FL-APP, enhancing A β plaque load and reactive astrocytic gliosis.

Kaden et al., [44] were the first to identify and characterize the K16N mutation, a lysine-to-asparagine substitution localized to the α -secretase cleavage site which causes early onset autosomal dominant dementia. The mutation increased A β toxicity and dramatically diminished α -cleavage and therefore α -CTF and sAPP α generation, resulting in levels 40-50% lower than those seen with APP wild type.

Conversely, in the search for low-frequency variants in the APP gene with significant effects on AD risk, Jonsson et al., [24] found the A673T coding mutation that protects against AD as well as age-related cognitive decline in the absence of AD. This substitution is adjacent to the β -site, and results in a reduction in A β production and a reduction of approximately 32% in the sAPP β /sAPP α ratio *in vitro* [25]. While the effects of these mutations appeared largely to be manifest in a reduction in sAPP β and β CTF production, they do suggest reduction of the sAPP β /sAPP α ratio by enhancement of sAPP α may have a similar effect. Interestingly, a recessive mutation at the same site - A673V - seen in an Italian family [45] causes enhanced A β production and fibril formation only when homozygous. When heterozygous, co-expression of wildtype APP and wildtype A β destabilizes aggregates and decreases toxicity, making this mutation either advantageous or disadvantageous with respect to AD, depending upon zygosity. This finding also suggests a new therapeutic strategy for destabilizing toxic aggregates in AD [46].

ApoE ϵ 4, SirT1 and sAPP α in AD

As described above, expression of the ApoE ϵ 4 allele confers a significant risk for development of AD, with 2/3 of all sporadic AD patients having one or two ApoE ϵ 4 alleles. Our recent studies have connected ApoE ϵ 4 expression with the major longevity determinants, sirtuins [47]. We showed that ApoE ϵ 4 - but not ApoE ϵ 3 - associates with APP with nanomolar affinity (K d ~80 nM), and that only ApoE ϵ 4 significantly reduces the sAPP α /A β ratio. In human glioblastoma A172 cells transfected with ApoE ϵ 3 or 4, ApoE ϵ 3 expression slightly, but not significantly, decreased sAPP α and increased A β 1-42; and ApoE ϵ 4 expression significantly decreased sAPP α by approximately 38% and increased A β 1-42 by 30%. Findings were similar for human neuroglioma H4 cells transfected with ApoE ϵ 3 or 4 and APP, with decreases for sAPP α and increases for A β 1-42 of 40% and 70%, respectively, in response to ApoE ϵ 4 expression. Also, only ApoE ϵ 4 expression significantly reduced SirT1 expression, triggered tau and APP phosphorylation, and induced programmed cell death. Others have supported these findings, including Lattanzio et al., [48] who showed decreased SirT1 mRNA in the frontal cortex of ApoE ϵ 4 mice, and Rhinn et al., who determined that the expression of several proteins that modulate APP processing and increase BACE activity and amyloid processing is altered by expression of ApoE ϵ 4 [49].

Sirtuins are NAD-dependent deacetylases that affect longevity and have a myriad of metabolic and stress-tolerance functions. Significant decreases in SirT1 levels in parietal cortex in AD patient tissue have been reported, and these decreases were closely correlated with duration of symptoms and tau accumulation [50]. We found similar

SirT1 decreases in temporoparietal cortex from AD patients; specifically, SirT1 - but not SirT2 or SirT6 - was significantly decreased by more than 60%. In addition, Kumar et al., [51] revealed a pronounced decline in SirT1 serum concentration in AD and MCI, as well as a more moderate decline in age-matched cognitively normal individuals.

Our studies reveal that ApoE ϵ 4 triggers a reduction in sAPP α levels by inhibiting the proteolysis of APP at the α -site and by reducing transcription of SirT1. As SirT1 has previously been shown to activate transcription of ADAM10 [52] and thus increase levels of neuroprotective sAPP α [53,54], one can conclude that a decrease in SirT1 expression as a result of the presence of ApoE ϵ 4 is likely to lead to decreased sAPP α levels. In further support of a role for ApoE ϵ 4 effects on SirT1 expression and ultimately sAPP α production, we showed that increasing SirT1 expression in the presence of ApoE ϵ 4 restores sAPP α levels *in vitro* by co-transfecting A172 cells with both ApoE ϵ 4 and SirT1 and identifying increases in sAPP α of 10% (1:1) or 20% (1:2) as compared to ApoE ϵ 4 transfection alone [47].

As a result of these findings, we added SirT1 enhancement as a target for our *in vitro* screens to identify new small molecules for potential development as AD therapeutics. This resulted in our identification of brain-permeable small molecules that increase SirT1, sAPP α , and cell survival *in vitro* (manuscript in preparation). In our ongoing studies, we plan to test these molecules *in vivo*, as well as screen a larger compound library to identify additional novel SirT1 enhancers.

TrkA overexpression decreases sAPP α


As described above, caspase cleavage of APP and generation of C31 is a toxic event that may result in cell death, therefore we have also screened compound libraries to identify molecules that block caspase cleavage and lower C31. Because C31 is very short-lived, we do this by assaying for the APPneo fragment that is also generated as a result of caspase cleavage. As described in Zhang et al., [55], we identified the Tropomyosin receptor kinase A (TrkA) inhibitor ADDN-1351 as being able to decrease APPneo *in vitro*. We also performed complementary *in vitro* studies wherein TrkA was over-expressed by co-transfection of 293T cells with TrkA and APP, resulting in a decrease in sAPP α production and an increase in the level of full-length APP. Treatment of these co-transfected cells with NGF at 5 nM, however, increased sAPP α production.

As ADDN-1351 was not brain penetrant and could not be tested *in vivo*, we tested the known TrkA inhibitor GW441756 in the J20 PDAPP mouse model of AD [56], and saw that it increased sAPP α , suggesting TrkA inhibition - rather than NGF activation - as a novel therapeutic approach to AD.

The finding that an inhibitor of the Nerve Growth Factor (NGF) receptor TrkA exerts anti-AD effects is, at first, counter-intuitive as it has been shown that reduction of TrkA-NGF interaction is associated with AD. In AD, however, Basal Forebrain Cholinergic Neurons (BFCN) degenerate due, in part, to impaired retrograde transport of NGF-TrkA complexes from BFCN targets. This may lead to accumulation of these complexes, over-activation, and C31 production. Hence, these complexes may have a paradoxical effect: under normal physiological conditions NGF signaling through TrkA may result in inhibition of the amyloidogenic pathway, but in AD, impaired retrograde transport of NGF-TrkA complexes may be deleterious.

sAPP α is a potent inhibitor of BACE

While sAPP α trophic effects alone would likely be of benefit in treatment of AD, sAPP α exerts additional anti-AD effects by reducing A β production. We recently reported that sAPP α is a potent endogenous inhibitor of the BACE enzyme [32], and that its inhibition is likely by an allosteric mechanism. Briefly, in these studies the inhibitory activity of sAPP α and sAPP β were compared to β -secretase inhibitor 1 in two different assays (Figure 2). In the first, Maltose Binding Protein fused to the C-terminal 125 residues (MBP-C125) of APP₆₉₅ was the substrate. In this assay, sAPP α , but not sAPP β , induced a dose-response inhibition of BACE cleavage with an IC₅₀ ~ 25 nM. In contrast, in our second assay which used the very short substrate P₅-P₅, sAPP α did not significantly inhibit BACE cleavage. This suggests the interaction of sAPP α that leads to inhibition of the enzyme is allosteric, that is, distal from the active site. sAPP β had no direct inhibitory effect on BACE in either assay. This data revealed a novel mechanistic role played by sAPP α in regulating overproduction of A β and restoring neuronal homeostasis and neuroprotection. Obregon et al., [31] also suggested sAPP α as an inhibitor of BACE and demonstrated that addition of exogenous sAPP α to APP-expressing CHO cells or over-expression of sAPP α in transgenic mice resulted in decreased BACE activity.



The direct inhibition of BACE by sAPP α indicates that it acts as an endogenous inhibitor ligand that can selectively regulate the proteolysis of APP. Our biochemical analysis reveals that sAPP α is an allosteric BACE inhibitor, showing an inhibitory profile similar to that of an exosite binding antibody [57]. Additionally, our Small-Angle X-ray Scattering (SAXS) analysis shows that sAPP α adopts a conformation distinct from the slightly shorter non-inhibitor sAPP β [32], and this conformational difference may explain their differing effects. BACE inhibition is an appealing strategy for AD therapeutic development. There are advanced BACE inhibitors currently in Phase 3 clinical trials, such as the Merck BACE inhibitor MK8931 [58]. All are directly active site-binding BACE inhibitors that interact with the catalytic dyad of the enzyme. It is hoped that these compounds will perform well in the clinic, but it is not improbable that they may be associated with unwanted side effects due to off-target cleavage inhibition of non-APP substrates. The APP-selective allosteric inhibition of BACE cleavage of APP may be associated with fewer risks for side effects.

sAPP α or ADAM10 enhancers in AD

We recently described the ability of tropisetron ("F03") the α_7 nicotinic Acetylcholine Receptor (α_7 nAChR) partial agonist and potent 5-HT₃ receptor antagonist to significantly increase sAPP α *in vitro* and *in vivo* in a mouse model of AD [59]. F03 (Figure 3A) was initially identified by screening a clinical compound library in Chinese Hamster Ovary cells stably transfected with human APP wildtype (CHO-7W) and determining sAPP α increases. F03 repeatedly increased sAPP α by 20-30%. sAPP α increases and A β reductions by F03 were seen in SH-SY5Y human neuroblastoma cells and in primary neuronal cultures from PDAPP J20 AD model mice [56]. Notably, F03 also increased sAPP α in A172 human glioblastoma cells stably transfected with ApoE ϵ 4 (Figure 3B).




Figure 3: The tropinol ester F03 increases sAPP α and improves cognition.

(A) Structure of Tropisetron (Trop, F03) a tropinol ester. (B) F03 restores sAPP α levels in the presence of ApoE ϵ 4 in human A172 neuroblastoma cells. (C) Meta analysis of more than 20 *in vivo* studies in J20 PDAPP AD model mice reveals F03 significantly increases sAPP α in combined hippocampus and entorhinal cortex. (D) F03 and an analog C41 significantly improved working object memory in old (>9mo) plaque-bearing J20 mice, and even improved memory in old Non-Transgenic (NTg) mice. This improvement in memory was closely related to increases in sAPP α as only sAPP α (E) was significantly increased, and A β 1-42 (F) was unchanged, although changes in *de novo* A β production may be difficult to detect in the presence of heavy plaque load.

Meta analysis of more than 20 *in vivo* studies in the AD model mice showed that F03 induces highly significant increases in sAPP α (Figure 3C), decreases A β 1-42, and increases the sAPP α /A β 1-42 ratio. F03 repeatedly increased cognitive performance in mice in the pre-plaque stage and, strikingly, it was able to improve cognition as

determined using the Novel Object Recognition (NOR) testing paradigm in old J20 AD model mice with extensive pre-existing A β plaque pathology (Figure 3D). This improvement in working object memory, as well as improvement in spatial memory as determined by Novel Location Recognition (not shown), was closely associated with increases in sAPP α (Figure 3E) as no significant decreases in A β were seen (Figure 3F). The effects of F03 *in vivo* were seen at low, human-equivalent doses used to treat Post-Operative Nausea and Vomiting (PONV), and as F03 is known to have a good safety profile, the drug is now in a clinical Phase 1b/2a in AD patients in Australia.

In our ongoing studies, we have generated and tested more than thirty F03 analogs and have noted the sAPP α -enhancing effects come largely from the 5-HT $_3$ antagonism, while the A β -lowering effects appear to arise from α_7 nAChR agonism. Surface Plasmon Resonance (SPR) shows F03 also interacts directly with APP and this, combined with multifunctional receptor interactions, seems to be critical for efficacy. In addition, F03 has been reported as an anti-inflammatory agent [60-62]. As chronic inflammation may be a factor contributing to the onset of AD [63], this drug may be of even greater utility in the treatment or prevention of AD.

Others are also identifying sAPP α enhancers. Lee et al., found that cilostazol attenuates A β production by increasing ADAM10 activity via SirT1-coupled Retinoic Acid Receptor- β (RAR β) activation in N2a cells expressing human APP Swedish (Swe) mutation [64]. Interestingly, in this study, SirT1 overexpression in N2a Swe cells also elevated ADAM10 and sAPP α levels.

Generally, retinoic acids are known to up regulate ADAM10 expression and/or activity [52]. Acitretin, a synthetic retinoid that is an approved drug for psoriasis, increases the ADAM10 gene expression. In a pilot Phase 2 clinical study in AD patients, acitretin was shown to significantly increase the sAPP α levels in CSF after a short period of treatment [65]. A longer term study on a larger patient cohort with this drug is planned.

Other molecules known to increase ADAM10 expression and/or activity include muscarinic agonists, neuropeptides such as Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), Protein Kinase C (PKC) activators, phosphatidylinositol 3-kinase, cAMP and calcium [66,67].

Ginsenoside Rh2, a ginseng derivative, was found to improve learning and memory in a mouse model of AD [68], and *in vitro* increased soluble sAPP α . Qiu et al., also used live-cell labeling to show plasma membrane APP levels increased and APP endocytosis decreased, and that this effect was likely due to a reduction in lipid raft levels. A green tea-derived polyphenolic compound (-)-epigallocatechin-3 gallate reduced A β *in vitro* and *in vivo* in an AD mouse model, in part by activation of estrogen receptor- α /phosphatidylinositol 3-kinase/protein kinase B signaling and by increasing ADAM10 processing [69].


Donecypride [70] a dual (h) 5-HT $_4$ R partial agonist also promotes sAPP α release and exerts pro-cognitive effects at 0.3 and 1 mg/kg in a mouse model of AD.

Baicalein, a flavonoid that modulates γ -Aminobutyric Acid (GABA) type A receptors, also increases sAPP α [71]. *In vitro*, baicalein significantly reduced the production of β -Amyloid (A β) by increasing APP α -processing. AD mice treated with baicalein for eight weeks showed enhanced APP α -secretase processing, reduced A β

production, and reduced AD-like pathology together with improved cognitive performance.

The Protein Kinase C (PKC) activator bryostatin-1, a macrolide lactone extract from a bryozoan species, has been shown to be effective in increasing sAPP α levels while reducing A β 40 and 42 in AD mouse models [72], and is currently in clinical trials for AD.

The structures of several of the small molecules shown to increase sAPP α *in vitro* and *in vivo* described above are shown in (Figure 4). Interestingly, two of these molecules, bryostatin-1 and acitretin, in addition to F03 (Figure 3A), have advanced into clinical testing in MCI and AD patients.



sAPP α and Cerebral Amyloid Angiopathy (CAA)

In CAA, the smooth muscle cells of the microvascular system degenerate and vessel wall components are replaced by A β . As little was known about the factors that induce CAA, Auerbach et al., [73] looked at the effects of anoxia on APP processing in a model of CAA and saw a decrease in expression of ADAM10 with an accompanying decrease in sAPP α and α CTF. While hypoxia did not change ADAM10 mRNA levels, there was a reduction in mature ADAM10. Thus, they revealed the requirement for oxygen in the regulation of the α -secretase pathway. Therefore, in conditions associated with lowering of blood oxygenation such as pulmonary

disease or with impaired vascular function such as cardiovascular disease, ADAM10 or sAPP α enhancement and ultimately restoration of a non-pathological sAPP β /sAPP α ratio may slow the accumulation of vascular amyloid and/or lower the risk of vascular dementia.

Enhancement of sAPP α in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disorder and the most common form of motor neuron disease. Recent studies indicate a role for APP and its cleavage products in the onset and progression of the disease, pointing to what may be overlap in the mechanisms that lead to ALS and AD. Therefore, compounds directed to modifying APP-related effects in AD may exert therapeutic effects in ALS as well. Since both A β increases and sAPP α decreases have recently been associated with ALS [74,75], we hypothesize that sAPP α enhancers such as F03 may be of benefit either as monotherapy or in combination therapy.

In Yoon et al., [76] it was revealed that A β interacts with Super Oxide Dismutase 1 (SOD1) resulting in a reduction in SOD activity, an increase in oxidative stress, and the compromised mitochondrial function that is characteristic of ALS [77,78]. In ALS model mice, APP and A β are both upregulated in spinal cord [74] and overexpression of A β has been shown to accelerate the onset of motor impairment [79]. Furthermore, the studies of Herman et al., [80] revealed that increasing A β 42 increased the Tar-DNA binding Protein (TDP43) inclusions found in the majority of ALS patients. Pathologically high A β concentrations exacerbate glutamate excitotoxicity at the Neuro-Muscular Junction (NMJ), a major contributor to motor neuron loss in ALS [81]. Reduction of A β production and trophic support by sAPP α enhancement may, therefore, be a new effective therapeutic strategy for ALS, at least as part of multimodal therapy. It has been shown that ICV treatment with a monoclonal antibody that blocks the β -secretase cleavage site on APP results in reduction of sAPP β and A β levels, and delays disease onset and deterioration in the pre-symptomatic stage of the disease in ALS mice [82].

sAPP α has several neuroprotective and/or trophic effects that may specifically be of benefit in ALS. Through receptor binding, it alters cyclic-GMP (cGMP) production and activates a cGMP-dependent Protein Kinase (PKG), promoting activation of the nuclear transcription factor NF- κ B. sAPP α has been found to protect neurons from proteasomal stress by inhibiting the stress-triggered pro-apoptotic c-Jun N-terminal Kinase (JNK)-signaling pathway. This may be of great utility in those cases of ALS wherein proteasomal stress is increased by accumulation of TDP43 and Fused-in-Sarcoma (FUS). This also suggests sAPP α enhancement may be of utility, at least as part of multi-model therapy, in Frontotemporal Dementia (FTD) where in TDP43 deposits are also found.

Some of the strongest evidence that sAPP α is implicated in ALS was revealed in Steinacker et al., wherein low CSF sAPP α levels were found to be tightly correlated with rapid disease progression. SirT1 expression was recently shown to ameliorate disease progression in a mouse model of ALS [83-85], indicating that sAPP α and/or SirT1 enhancement might both be effective as part of ALS therapy.

sAPP α , Traumatic Brain Injury (TBI) and stroke

TBI triggers a sequence of events starting with tissue damage and resulting frequently in the breaching of the Blood-Brain Barrier (BBB) and deprivation of blood flow to tissue, followed by an inflammatory response that includes microglial activation, reactive astrocytic

gliosis, and ultimately glial scarring [86]. A history of TBI increases risk for later development of AD, particularly in individuals expressing the ApoE ϵ 4 allele [87] and this has recently been the focus of much attention [88]. The increased risk is thought to be due, in part, to increased APP expression, BACE activity, and A β production post-injury [89].

The upregulation of APP may lead to concomitantly increased sAPP α and A β , indicating that both may play a role in response to TBI [40]. And while there may be a protective role for increased A β production acutely post-TBI [90-92], ongoing increases in A β production are likely deleterious and increase the risk for later development of AD. The restoration of trophic pre-injury APP processing may improve outcome. Based on this hypothesis, Thornton et al., [93] introduced sAPP α ICV post-trauma to rats with induced TBI. The results included significantly improved motor outcome in rotorod testing, reduction of the number of apoptotic neuronal perikarya in hippocampus and cortex, and reduced axonal injury within the corpus callosum, revealing it to be a promising therapeutic strategy for TBI.

The benefits of increasing sAPP α after a hypoxic event such as TBI or stroke may partially be attributed to its inhibition of BACE. As we posit in Peters-Libeu et al., [32] the inhibition of BACE by sAPP α may be part of an evolutionarily-conserved hypoxia response pathway. Hypoxia-Inducible Factor (HIF)-1 has been shown to upregulate both BACE and APP expression in zebra fish [94] and in mammalian cell culture [95]. Similarly, production of both BACE and APP have been shown to be up-regulated in response to hypoxia in the developing rat brain and in mature rats [96], leading to increased production of A β peptide. In addition, suppression of HIF-1 has been shown to decrease BACE production and increase sAPP α production [97].

An exaggerated inflammatory response also contributes to poorer outcome post-TBI, in part due to a reduction in sAPP α production. Therefore sAPP α may act as a modulator of inflammation. Siopi et al., [98] studied the effects of the α -secretase activator etazolate on acute and post-TBI outcome in a mouse model. Within a therapeutic window of two hours, a single dose of etazolate reduced inflammation and edema, and improved memory and locomotion, with these effects closely associated with restoration of sAPP α levels.

sAPP α , sleep and melatonin

Chronic stress, metabolic impairment and sleep disorders can lower α - and increase β -processing of APP [99] and increase risk of AD [100]. Melatonin, a key regulator of circadian rhythm and sleep, decreases with age and in patients with AD [101,102] and treatment with melatonin can reduce A β aggregation and toxicity [103]. Shukla et al., [104] revealed melatonin stimulates α -secretase cleavage of APP and sAPP α production in cultured neuronal and non-neuronal cells by upregulating both ADAM10 and ADAM17. These effects may explain the correlation of sleep disorders and an increased risk of cognitive impairment, as melatonin and therefore sAPP α levels typically peak in the middle of the night, perhaps as part of memory consolidation during sleep. Therefore, a sAPP α enhancer could be an integral part of treatment of sleep disorders and may lower the risk for AD.

Conclusion

The dominant paradigm in AD research posits accumulation of A β in brain as the key biochemical event underlying the development of AD, and thus is a primary target for drug development. Yet targeting

A β production and/or clearance has, to date, resulted in clinical failure in treatment of AD. This could very well be due to inadequate target engagement by the therapeutics or drug-related side effects rendering the treatment modality ineffective. Successful clearance of amyloid by antibody treatment such as with bapineuzumab has been shown to be associated with Amyloid-Related Imaging Abnormalities-Edema/Effusion (ARIA-E), apparently reflecting microhemorrhage. Similarly, off-target effects of the γ -secretase inhibitors due to inhibition of cleavage of non-APP substrates such as Notch 1 resulted in significant side effects for this approach. Other failures may be due to trial participant selection or screening, particularly when participants with AD-symptomatology do not have amyloid pathology. PET amyloid imaging is being used to eliminate this issue.

Timing of treatment may also likely be a critical factor leading to clinical trial failure. By the time an AD diagnosis is made, there is already significant neuronal death and neurofibrillary tangle formation, which A β -lowering alone cannot reverse. Therefore, to test the amyloid hypothesis, it would be ideal to commence anti-A β or amyloid treatment before significant damage has occurred, but in a patient population where the onset of amyloid pathology is almost certain. In a current study that is addressing these issues, individual members of families in Colombia expressing a genetic mutation resulting in increased A β production are being treated pre-symptomatically with the humanized antibody crenezumab. In addition, the ongoing anti-amyloid treatment in the asymptomatic AD "A4" study - a 3-year prevention trial in PET-positive 65-85 year-old participants with the A β antibody solanezumab-targets older individuals with normal cognition but at risk of developing sporadic AD. In this case, appropriate study participants are identified by pre-study amyloid PET imaging.

BACE inhibitors are currently in clinical trials and still hold great promise, but again may be limited in use by off-target side effects. Even if these inhibitors provide some benefit, as we hope, it is likely combination therapy will be necessary to achieve a truly significant effect. As a result, there is an urgent need to identify new approaches for the treatment of AD, and it is possible that targeting sAPP α enhancement will be advantageous, improving cognitive performance while at the same time decreasing A β production by an endogenously relevant mechanism. We propose that a sAPP α -enhancer would be effective as a monotherapy or as part of multi-modal therapy in AD. This enhancement may be induced by treatment with a variety of molecules as described in this review that increase sAPP α . Furthermore, sAPP α enhancement may also be an effective therapeutic approach in treatment of TBI, ALS, CAA, and stroke.

Acknowledgements

This work was supported by grants from the Mary S. Easton Center for Alzheimer's Disease Research, Rosenberg Alzheimer's Project, the Joseph Drown Foundation, Acceleration Partners, R21AG041456 from NIA, R01AG034427 from NIA, Bechtel Foundation and Alzheimer's Drug Discovery Foundation (ADDF).

References

1. Alzheimer's Association (2015) 2015 Alzheimer's disease facts and figures. *Alzheimers Dement* 11: 332-384.
2. Ikeda S, Wong CW, Allsop D, Landon M, Kidd M, et al. (1987) Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-beta protein monoclonal antibody. *Lab Invest* 57: 446-449.

3. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends Pharmacol Sci* 12: 383-388.
4. Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer's disease. *Trends Neurosci* 16: 460-465.
5. Dickson DW (1997) Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? *Am J Pathol* 151: 7-11.
6. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. *Neuron* 44: 181-193.
7. Devi L, Ohno M (2013) Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. *Neurobiol Learn Mem* 102: 7-11.
8. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, et al. (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. *Proc Natl Acad Sci USA* 109: 2895-2903.
9. Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P (2013) Anti-diabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease. *Discov Med* 16: 277-286.
10. Hölscher C (2014) First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. *Alzheimers Dement* 10: 33-37.
11. Eketjäll S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, et al. (2013) AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different *in vivo* models and reduced amyloid deposition in Tg2576 mice. *J Neurosci* 33: 10075-10084.
12. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, et al. (2011) Robust central reduction of amyloid- β in humans with an orally available, non-peptidic β -secretase inhibitor. *J Neurosci* 31: 16507-16516.
13. Wyss DF, Wang YS, Eaton HL, Strickland C, Voigt JH, et al. (2012) Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors. *Top Curr Chem* 317: 83-114.
14. Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, et al. (2013) ABPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for Alzheimer's disease. *J Alzheimers Dis* 37: 343-355.
15. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem Biophys Res Commun* 120: 885-890.
16. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, et al. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA* 82: 4245-4249.
17. Butterfield DA, Reed T, Newman SF, Sultana R (2007) Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. *Free Radic Biol Med* 43:658-677.
18. Parameshwaran K, Dhanasekaran M, Suppiramaniam V (2008) Amyloid beta peptides and glutamatergic synaptic dysregulation. *Exp Neurol* 210: 7-13.
19. Rosales-Corral S, Tan DX, Reiter RJ, Valdivia-Velázquez M, Acosta-Martínez JP, et al. (2004) Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-beta onto the hippocampus *in vivo*. *J Neuroimmunol* 150: 20-28.
20. Canevari L, Clark JB, Bates TE (1999) beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. *FEBS Lett* 457: 131-134.
21. Lin H, Bhatia R, Lal R (2001) Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. *FASEB J* 15: 2433-2444.
22. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV (2000) Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. *Acta Neurol Scand Suppl* 176: 53-59.

23. Galimberti D, Scarpini E (2010) Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. *Int J Clin Exp Med* 3: 129-143.
24. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature* 488: 96-99.
25. Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, et al. (2014) Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. *J Biol Chem* 289: 30990-31000.
26. Sadigh-Eteghad S, Talebi M, Farhoudi M (2012) Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease. A meta-analysis. *Neurosciences (Riyadh)* 17: 321-326.
27. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. *Cold Spring Harb Perspect Med* 2: 006312.
28. Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, et al. (2012) An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. *Ann Neurol* 71: 765-775.
29. Das U, Scott DA, Ganguly A, Koo EH, Tang Y, et al. (2013) Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. *Neuron* 79: 447-460.
30. Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, et al. (2012) ADAM10 expression and promoter haplotype in Alzheimer's disease. *Neurobiol Aging* 33: 2229.
31. Obregon D, Hou H, Deng J, Giunta B, Tian J, et al. (2012) Soluble amyloid precursor protein- α modulates β -secretase activity and amyloid- β generation. *Nat Commun* 3: 777.
32. Peters-Libeu C, Jesus C, Mitsumori M, Poksay K, Spilman P, et al. (2015) sAPP α is a potent endogenous inhibitor of BACE 1. *J Alzheimer's disease JAD Preprint*: 1-11.
33. Tian Y, Crump CJ, Li YM (2010) Dual role of alpha-secretase cleavage in the regulation of gamma-secretase activity for amyloid production. *J Biol Chem* 285: 32549-32556.
34. Chasseigneaux S, Allinquant B (2012) Functions of A β , sAPP α and sAPP β : similarities and differences. *J Neurochem* 120: 99-108.
35. Ortega F, Stott J, Visser SA, Bendtsen C (2013) Interplay between α -, β -, and γ -secretases determines biphasic amyloid- β protein level in the presence of a γ -secretase inhibitor. *J Biol Chem* 288: 785-792.
36. Gralle M, Botelho MG, Wouters FS (2009) Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. *J Biol Chem* 284: 15016-15025.
37. Mattson MP, Furukawa K (1998) Signaling events regulating the neurodevelopmental triad. Glutamate and secreted forms of beta-amyloid precursor protein as examples. *Perspect Dev Neurobiol* 5: 337-352.
38. Claassen AM, Guévremont D, Mason-Parker SE, Bourne K, Tate WP, et al. (2009) Secreted amyloid precursor protein- α upregulates synaptic protein synthesis by a protein kinase G-dependent mechanism. *Neurosci Lett* 460: 92-96.
39. Anderson JJ, Holtz G, Baskin PP, Wang R, Mazzarelli L, et al. (1999) Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits. *Neuroscience* 93: 1409-1420.
40. Corrigan F, Vink R, Blumbergs PC, Masters CL, Cappai R, et al. (2012) Characterisation of the effect of knockout of the amyloid precursor protein on outcome following mild traumatic brain injury. *Brain Res* 1451: 87-99.
41. Hick M, Herrmann U, Weyer SW, Mallm JP, Tschäpe JA, et al. (2015) Acute function of secreted amyloid precursor protein fragment APPs α in synaptic plasticity. *Acta Neuropathol* 129: 21-37.
42. Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO, et al. (1997) Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. *Arch Neurol* 54: 641-644.
43. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, et al. (2013) ADAM10 missense mutations potentiate β -amyloid accumulation by impairing prodomain chaperone function. *Neuron* 80: 385-401.
44. Kaden D, Harmeier A, Weise C, Munter LM, Althoff V, et al. (2012) Novel APP/A β mutation K16N produces highly toxic heteromeric A β oligomers. *EMBO Mol Med* 4: 647-659.
45. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, et al. (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. *Science* 323: 1473-1477.
46. Di Fede G, Catania M, Morbin M, Giaccone G, Moro ML, et al. (2012) Good gene, bad gene: new APP variant may be both. *Prog Neurobiol* 99: 281-292.
47. Theendakara V, Patent A, Peters Libeu CA, Philpot BD, Flores S, et al. (2013) Neuroprotective Sirtuin ratio reversed by ApoE4. *Proc Natl Acad Sci USA* 110: 18303-18308.
48. Lattanzio F, Carboni L, Carretta D, Rimondini R, Candeletti S, et al. (2014) Human apolipoprotein E4 modulates the expression of Pin1, Sirtuin 1, and Presenilin 1 in brain regions of targeted replacement apoE mice. *Neuroscience* 256: 360-369.
49. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, et al. (2013) Integrative genomics identifies APOE ϵ 4 effectors in Alzheimer's disease. *Nature* 500: 45-50.
50. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr, et al. (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. *J Neuropathol Exp Neurol* 68: 48-58.
51. Kumar R, Chatterjee P, Sharma PK, Singh AK, Gupta A, et al. (2013) Sirtuin1: a promising serum protein marker for early detection of Alzheimer's disease. *PLoS One* 8: 61560.
52. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F (2009) Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. *FASEB J* 23: 1643-1654.
53. Donmez G, Wang D, Cohen DE, Guarente L (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. *Cell* 142: 320-332.
54. Donmez G (2013) Sirtuins as possible targets in neurodegenerative diseases. *Curr Drug Targets* 14: 644-647.
55. Zhang Q, Descamps O, Hart MJ, Poksay KS, Spilman P, et al. (2014) Paradoxical effect of TrkA inhibition in Alzheimer's disease models. *J Alzheimers Dis* 40: 605-617.
56. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, et al. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. *Proc Natl Acad Sci USA* 96: 3228-3233.
57. Wang W, Liu Y, Lazarus RA (2013) Allosteric inhibition of BACE1 by an exosite-binding antibody. *Curr Opin Struct Biol* 23: 797-805.
58. Cumming JN, Smith EM, Wang L, Misiaszek J, Durkin J, et al. (2012) Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. *Bioorg Med Chem Lett* 22: 2444-2449.
59. Spilman P, Descamps O, Gorostiza O, Peters-Libeu C, Poksay KS, et al. (2014) The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. *Brain Res* 1551: 25-44.
60. Fiebich BL, Akundi RS, Lieb K, Candelario-Jalil E, Gmeiner D, et al. (2004) Antiinflammatory effects of 5-HT $_3$ receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. *Scand J Rheumatol Suppl* 119: 28-32.
61. Setoguchi D, Nakamura M, Yatsuki H, Watanabe E, Tateishi Y, et al. (2011) Experimental examination of anti-inflammatory effects of a 5-HT $_3$ receptor antagonist, tropisetron, and concomitant effects on autonomic nervous function in a rat sepsis model. *Int Immunopharmacol* 11: 2073-2078.
62. Tasaka Y, Yasunaga D, Kiyoi T, Tanaka M, Tanaka A, et al. (2015) Involvement of stimulation of α 7 nicotinic acetylcholine receptors in the suppressive effect of tropisetron on dextran sulfate sodium-induced colitis in mice. *J Pharmacol Sci* 127: 275-283.

63. Meraz-Ríos MA, Toral-Ríos D, Franco-Bocanegra D, Villeda-Hernández J, Campos-Peña V (2013) Inflammatory process in Alzheimer's Disease. *Front Integr Neurosci* 7: 59.
64. Lee HR, Shin HK, Park SY, Kim HY, Lee WS, et al. (2014) Cilostazol suppresses β -amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor- β . *J Neurosci Res* 92: 1581-1590.
65. Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, et al. (2014) Increased CSF APPs- α levels in patients with Alzheimer disease treated with acitretin. *Neurology* 83: 1930-1935.
66. Postina R (2012) Activation of α -secretase cleavage. *J Neurochem* 120: 46-54.
67. Endres K, Fahrenholz F (2012) Regulation of α -secretase ADAM10 expression and activity. *Exp Brain Res* 217: 343-352.
68. Qiu J, Li W, Feng SH, Wang M, He ZY (2014) Ginsenoside Rh2 promotes nonamyloidogenic cleavage of amyloid precursor protein via a cholesterol-dependent pathway. *Genet Mol Res* 13:3586-3598.
69. Zhang SQ, Sawmiller D, Li S, Rezai-Zadeh K, Hou H, et al. (2013) Octyl gallate markedly promotes anti-amyloidogenic processing of APP through estrogen receptor-mediated ADAM10 activation. *PLoS One* 8: 71913.
70. Lecoutey C, Hedou D, Freret T, Giannoni P, Gaven F, et al. (2014) Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. *Proc Natl Acad Sci USA* 111: 3825-3830.
71. Zhang SQ, Obregon D, Ehrhart J, Deng J, Tian J, et al. (2013) Baicalein reduces β -amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer's disease transgenic mouse model. *J Neurosci Res* 91: 1239-1246.
72. Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, et al. (2004) Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. *Proc Natl Acad Sci USA* 101: 11141-11146.
73. Auerbach ID, Vinters HV (2006) Effects of anoxia and hypoxia on amyloid precursor protein processing in cerebral microvascular smooth muscle cells. *J Neuropathol Exp Neurol* 65: 610-620.
74. Bryson JB, Hobbs C, Parsons MJ, Bosch KD, Pandraud A, et al. (2012) Amyloid Precursor Protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *Hum Mol Genet* 21: 3871-3882.
75. Steinacker P, Fang L, Kuhle J, Petzold A, Tumani H, et al. (2011) Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. *PLoS One* 6: 23600.
76. Yoon EJ, Park HJ, Kim GY, Cho HM, Choi JH, et al. (2009) Intracellular amyloid beta interacts with SOD1 and impairs the enzymatic activity of SOD1: implications for the pathogenesis of amyotrophic lateral sclerosis. *Exp Mol Med* 41: 611-617.
77. Valentine JS, Doucette PA, Zittin Potter S (2005) Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. *Annu Rev Biochem* 74: 563-593.
78. Vehviläinen P, Koistinaho J, Gundars G (2014) Mechanisms of mutant SOD1 induced mitochondrial toxicity in amyotrophic lateral sclerosis. *Front Cell Neurosci* 8: 126.
79. Li QX, Mok SS, Laughton KM, McLean CA, Volitakis I, et al. (2006) Overexpression of A β is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. *Aging Cell* 5:153-165.
80. Herman AM, Khandelwal PJ, Stanczyk BB, Rebeck GW, Moussa CE (2011) β -amyloid triggers ALS-associated TDP-43 pathology in AD models. *Brain Res* 1386: 191-199.
81. Combes M, Poindron P, Callizot N (2015) Glutamate protects neuromuscular junctions from deleterious effects of β -amyloid peptide and conversely: an *in vitro* study in a nerve-muscle coculture. *J Neurosci Res* 93: 633-643.
82. Rabinovich-Toidman P, Becker M, Barbiro B, Solomon B (2012) Inhibition of amyloid precursor protein beta-secretase cleavage site affects survival and motor functions of amyotrophic lateral sclerosis transgenic mice. *Neurodegener Dis* 10: 30-33.
83. Watanabe S, Ageta-Ishihara N, Nagatsu S, Takao K, Komine O, et al. (2014) SIRT1 overexpression ameliorates a mouse model of SOD1-linked amyotrophic lateral sclerosis via HSF1/HSP70i chaperone system. *Mol Brain* 7: 62.
84. Song L, Liang C, Zhang X, Li J, Le W (2014) Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *Biomed Res Int* 483501.
85. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. *EMBO J* 26: 3169-3179.
86. Dombovy ML (2011) Traumatic brain injury. *Continuum (Minneapolis)* 17: 584-605.
87. Yang ST, Hsiao IT, Hsieh CJ, Chiang YH, Yen TC, et al. (2015) Accumulation of amyloid in cognitive impairment after mild traumatic brain injury. *J Neurol Sci* 349: 99-104.
88. Shively S, Scher AI, Perl DP, Diaz-Arrastia R (2012) Dementia resulting from traumatic brain injury: what is the pathology? *Arch Neurol* 69: 1245-1251.
89. Olsson A, Csajbok L, Ost M, Höglund K, Nylén K, et al. (2004) Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. *J Neurol* 251: 870-876.
90. Mannix RC, Zhang J, Berglass J, Qui J, Whalen MJ (2013) Beneficial effect of amyloid beta after controlled cortical impact. *Brain Inj* 27: 743-748.
91. Mannix RC, Zhang J, Park J, Lee C, Whalen MJ (2011) Detrimental effect of genetic inhibition of B-site APP-cleaving enzyme 1 on functional outcome after controlled cortical impact in young adult mice. *J Neurotrauma* 28: 1855-1861.
92. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. *PLoS One* 5: 9505.
93. Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C (2006) Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. *Brain Res* 1094: 38-46.
94. Moussavi Nik SH, Wilson L, Newman M, Croft K, Mori TA, et al. (2012) The BACE1-PSEN-A β PP regulatory axis has an ancient role in response to low oxygen/oxidative stress. *J Alzheimers Dis* 28: 515-530.
95. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, et al. (2007) Hypoxia-Inducible Factor 1 α (HIF-1 α)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. *J Biol Chem* 282: 10873-10880.
96. Nalivaeva NN, Turner AJ (2013) The amyloid precursor protein: a biochemical enigma in brain development, function and disease. *FEBS Lett* 587: 2046-2054.
97. Li QY, Wang HM, Wang ZQ, Ma JF, Ding JQ, et al. (2010) Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells. *Neurosci Lett* 481: 154-158.
98. Siopi E, Llufrú-Dabén G, Cho AH, Vidal-Lletjós S, Plotkine M, et al. (2013) Etazolate, an α -secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. *Neuropharmacology* 67: 183-192.
99. Agostinho P, Pliássova A, Oliveira CR, Cunha RA (2015) Localization and Trafficking of Amyloid- β Protein Precursor and Secretases: Impact on Alzheimer's Disease. *J Alzheimers Dis* 45: 329-347.
100. Musiek ES, Xiong DD, Holtzman DM (2015) Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. *Exp Mol Med* 47: 148.

101. Ozcankaya R, Delibas N (2002) Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. *Croat Med J* 43: 28-32.
102. Ferrari E, Arcaini A, Gornati R, Pelanconi L, Cravello L, et al. (2000) Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. *Exp Gerontol* 35: 1239-1250.
103. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, et al. (2009) Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. *J Pineal Res* 47: 82-96.
104. Shukla M, Htoo HH, Wintachai P, Hernandez JF, Dubois C, et al. (2015) Melatonin stimulates the nonamyloidogenic processing of β APP through the positive transcriptional regulation of ADAM10 and ADAM17. *J Pineal Res* 58: 151-165.